Context Despite the large body of literature on breakthrough cancer pain (BTcP), an
accurate estimate of BTcP prevalence is still not available. Objectives To provide an …

Fentanyl is a strong opioid that is available for various administration routes, and which is
widely used to treat cancer‐related pain. Many factors influence the fentanyl …

According to a systematic review of the literature, pain prevalence ranges from 33% in
patients after curative treatment to 59% in patients on anticancer treatment and to 64% in …

Background Morphine stimulates angiogenesis and cancer progression in mice. We
investigated whether morphine influences tumour onset, development, and animal model …

Breakthrough cancer pain (BTcP) is an episode of severe pain that “breaks through” a
period of persistent pain at least partly controlled by a stable opioid regimen. Although …

Tapentadol is an analgesic compound that acts centrally to attenuate pain. Previous studies
have shown that tapentadol has dual mechanisms of action as a mu-opioid receptor agonist …

Objectives: To explore the effect of breakthrough cancer pain (BTcP) treatment on quality of
sleep and other aspects of the health-related quality of life (HRQoL) in patients with cancer …

Abstract Context Breakthrough cancer pain (BTcP) is widely recognized as a clinically
significant complication of chronic cancer pain. With most BTcP episodes peaking in …

There has been a paradigm shift in medicine away from tradition, anecdote and theoretical
reasoning from the basic sciences towards evidence-based medicine (EBM). In palliative …

Background: The aim of this study was to identify potential variables influencing the clinical
presentation of breakthrough cancer pain (BTP). Methods: Cancer patients with a diagnosis …